{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:41:25Z","timestamp":1792474885862,"version":"4.5.0"},"reference-count":31,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014489","name":"Johnson and Johnson Pharmaceutical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Real-world outcome data for patients with FGFR gene alteration\u2013positive (FGFRalt) advanced\/metastatic solid tumors after standard-of-care (SOC) exhaustion are lacking. De-identified data from a custom-curated Flatiron Health Foundation Medicine Clinico\u2013Genomic database were used in this retrospective, noninterventional, observational study. Eligible patients were \u226518 years of age with FGFRalt advanced\/metastatic disease who had exhausted SOC treatment. Real-world overall survival (rwOS), progression-free survival (rwPFS), and treatment patterns were assessed. Primary analyses were weighted for tumor types in the RAGNAR clinical trial (NCT04083976) and accounted for delayed study entry. Data from 230 patients (FGFR fusions: 68.3%; FGFR mutations: 37%) across 18 tumor types were analyzed. In primary analyses, the median (95% confidence interval) rwOS was 183 (148\u2013236) days, and the median rwPFS was 87 (63\u2013196) days. The median rwOS ranged from 86 [41\u2013not available (NA)] to 356 (299\u2013NA) days across tumor types and was 161 (106\u2013212) days for patients with FGFR fusions and 236 (82\u2013538) days for patients with FGFR mutations. Most patients had received one (67.4%) or two (18.2%) lines of therapy\/treatment blocks at SOC exhaustion. From first-line therapy to SOC exhaustion, most common treatments were chemotherapy (100%) and immunotherapy (17.4%), and from best supportive care after SOC exhaustion to death was chemotherapy (65.2%), immunotherapy (16.1%), and a clinical trial drug (15.5%). These real-world survival and treatment-pattern findings highlight the poor prognosis of and unmet medical needs for patients with FGFRalt advanced\/metastatic solid tumors who have exhausted SOC treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Findings from this real-world study\u2014that patients with FGFRalt advanced\/metastatic solid tumors have poor prognosis after SOC therapy exhaustion\u2014contextualize results from the RAGNAR trial and suggest improved outcomes with erdafitinib. The rarity and poor prognosis of FGFR alterations highlight why randomized controlled trials in this population may be infeasible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0233","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:18:09Z","timestamp":1791001089000},"page":"2451-2462","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Real-World Study of Patients with FGFR-Altered Advanced Solid Tumors after Exhaustion of Standard-of-Care Treatment"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1854-3658","authenticated-orcid":false,"given":"Levon","family":"Demirdjian","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States) , Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8983-6052","authenticated-orcid":false,"given":"Hussein","family":"Sweiti","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States) , Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-519X","authenticated-orcid":false,"given":"Raymond","family":"Harvey","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States) , Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6200-6952","authenticated-orcid":false,"given":"Kristopher","family":"Standish","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States) , Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0933-222X","authenticated-orcid":false,"given":"Nicole","family":"Stone","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States) , Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8546-4617","authenticated-orcid":false,"given":"Simona","family":"Baculea","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States) , Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6567-4266","authenticated-orcid":false,"given":"Joel","family":"Greshock","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States) , Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5599-5393","authenticated-orcid":false,"given":"Spyros","family":"Triantos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States) , Spring House, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"2026102001352415600_bib1","doi-asserted-by":"publisher","first-page":"e19541","DOI":"10.1016\/j.heliyon.2023.e19541","article-title":"Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas","volume":"9","author":"Wekking","year":"2023","journal-title":"Heliyon"},{"key":"2026102001352415600_bib2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/cells10051201","article-title":"Fibroblast growth factor receptors (FGFRs) and noncanonical partners in cancer signaling","volume":"10","author":"Ferguson","year":"2021","journal-title":"Cells"},{"key":"2026102001352415600_bib3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/cancers17010082","article-title":"The complexity and significance of fibroblast growth factor (FGF) signaling for FGF-targeted cancer therapies","volume":"17","author":"Nguyen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026102001352415600_bib4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/ijms25020849","article-title":"Molecular targeting of the fibroblast growth factor receptor pathway across various cancers","volume":"25","author":"Shan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026102001352415600_bib5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026102001352415600_bib6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"key":"2026102001352415600_bib7","doi-asserted-by":"publisher","first-page":"6856","DOI":"10.3390\/ijms21186856","article-title":"FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention","volume":"21","author":"De Luca","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026102001352415600_bib8","doi-asserted-by":"publisher","first-page":"105561","DOI":"10.1016\/j.esmoop.2025.105561","article-title":"FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling","volume":"10","author":"Lyu","year":"2025","journal-title":"ESMO Open"},{"key":"2026102001352415600_bib9","doi-asserted-by":"publisher","first-page":"644854","DOI":"10.3389\/fonc.2021.644854","article-title":"A pancancer analysis of the expression landscape and clinical relevance of fibroblast growth factor receptor 2 in human cancers","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"2026102001352415600_bib10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2025.04.005","article-title":"Clinical and genomic landscape of FGFR3 alterations across different stages of urothelial cancer","volume":"77","author":"Haas","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"2026102001352415600_bib11","doi-asserted-by":"publisher","first-page":"107230","DOI":"10.1016\/j.phrs.2024.107230","article-title":"Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma","volume":"205","author":"Song","year":"2024","journal-title":"Pharmacol Res"},{"key":"2026102001352415600_bib12","doi-asserted-by":"publisher","first-page":"102054","DOI":"10.1016\/j.clgc.2024.02.005","article-title":"Prognostic value of fibroblast growth factor receptor genetic alterations in metastatic urothelial carcinoma","volume":"22","author":"Fleming","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2026102001352415600_bib13","doi-asserted-by":"publisher","first-page":"102174","DOI":"10.1016\/j.clgc.2024.102174","article-title":"The impact of fibroblast growth factor receptor alterations in clinical outcomes of patients with advanced urothelial carcinoma: real-world data from a Latin American population","volume":"22","author":"Souza","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2026102001352415600_bib14","doi-asserted-by":"publisher","first-page":"501719","DOI":"10.1016\/j.acuroe.2025.501719","article-title":"Biological and therapeutic implications of FGFR alterations in urothelial cancer: a systematic review from non-muscle-invasive to metastatic disease","volume":"49","author":"Pichler","year":"2025","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"2026102001352415600_bib15","doi-asserted-by":"publisher","first-page":"e70546","DOI":"10.1002\/cam4.70546","article-title":"Prognostic impact of oncogenic fibroblast growth factor receptor alterations in patients with advanced solid tumors in a real-world setting","volume":"14","author":"Demirdjian","year":"2025","journal-title":"Cancer Med"},{"key":"2026102001352415600_bib16","doi-asserted-by":"publisher","first-page":"1137510","DOI":"10.3389\/fonc.2023.1137510","article-title":"Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue","volume":"13","author":"Brandi","year":"2023","journal-title":"Front Oncol"},{"key":"2026102001352415600_bib17","doi-asserted-by":"publisher","first-page":"e2100414","DOI":"10.1200\/PO.21.00414","article-title":"Progression-free survival in patients with cholangiocarcinoma with or without FGF\/FGFR alterations: a FIGHT-202 post hoc analysis of prior systemic therapy response","volume":"6","author":"Bibeau","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026102001352415600_bib18","article-title":"PEMAZYRE\u00ae (pemigatinib) [package insert]","year":"2022"},{"key":"2026102001352415600_bib19","article-title":"LYTGOBI\u00ae (futibatinib) [package insert]","year":"2024"},{"key":"2026102001352415600_bib20","article-title":"BALVERSA\u00ae (erdafitinib) [package insert]","year":"2014"},{"key":"2026102001352415600_bib21","article-title":"FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma","author":"US Food and Drug Administration","year":"2024"},{"key":"2026102001352415600_bib22","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102001352415600_bib23","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026102001352415600_bib24","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41416-022-01920-5","article-title":"Confidence bands in survival analysis","volume":"127","author":"Sachs","year":"2022","journal-title":"Br J Cancer"},{"key":"2026102001352415600_bib25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"2026102001352415600_bib26","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/jnci\/djt211","article-title":"Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival","volume":"105","author":"Chubak","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2026102001352415600_bib27","article-title":"Characterization and survival outcome of missing Ecog performance status in a real-world cohort of advanced non-small cell lung cancer patients","volume":"2573","author":"Zhang","year":"2025","journal-title":"Public Health Theses"},{"key":"2026102001352415600_bib28","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.3390\/app13106209","article-title":"A natural language processing algorithm to improve completeness of ECOG performance status in real-world data","volume":"13","author":"Cohen","year":"2023","journal-title":"Appl Sci"},{"key":"2026102001352415600_bib29","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/1078-0432.CCR-24-2015","article-title":"Characterization of FGFR alterations and activation in patients with high-risk non-muscle-invasive bladder cancer","volume":"30","author":"Eisner","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026102001352415600_bib30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"2026102001352415600_bib31","doi-asserted-by":"publisher","first-page":"e2400896","DOI":"10.1200\/PO-24-00896","article-title":"Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies: a pooled analysis of early-phase clinical trials","volume":"9","author":"Grochot","year":"2025","journal-title":"JCO Precis Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0233\/3834966\/crc-26-0233.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2451\/3840302\/crc-26-0233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2451\/3840302\/crc-26-0233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:35:27Z","timestamp":1792474527000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2451\/789460\/A-Real-World-Study-of-Patients-with-FGFR-Altered"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0233","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8784612","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34709037","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709004","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709016","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709112","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709100","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709022","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709031","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709076","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709043","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709085","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709052","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709094","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709061","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34709070","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}